-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News, June 24, after a whole day of intense and fierce confrontation, on the evening of June 23, Shanghai Sunshine Pharmaceutical Purchasing Network "overtime" announced overnight the results of the fifth batch of 62 nationally sourced varieties of the proposed selection.
3 days
.
Judging from the results of official announcements, a total of 61 products to be selected involve 148 companies, with an average price reduction of 56%
.
Among them, Qilu Pharmaceutical's rivaroxaban (10mg) successfully defeated the original research drug manufacturer Bayer with a 98% price reduction, becoming the highest drop in this round of nationally collected varieties
.
3 days
.
Judging from the results of official announcements, a total of 61 products to be selected involve 148 companies, with an average price reduction of 56%
.
Among them, Qilu Pharmaceutical's rivaroxaban (10mg) successfully defeated the original research drug manufacturer Bayer with a 98% price reduction, becoming the highest drop in this round of nationally collected varieties
.
At this point, the fifth batch of nationally sourced varieties that have attracted much attention from the industry has basically settled
.
According to reports, the nationally-sourced varieties have accounted for nearly 1/3 of the total purchase amount of chemical drugs in public hospitals
.
It is noteworthy that this time when injections accounted for more than half, the number of foreign-funded pharmaceutical companies to choose from has increased significantly, and most of them are injections
.
However, Pfizer, AZ, etc.
finally unexpectedly did not appear in the list of candidates
.
With reference to the selection of the first four batches of national procurement, this means that at the beginning of a new day, the pharmaceutical market with a purchase amount of 55 billion yuan will gradually be reshaped
.
.
According to reports, the nationally-sourced varieties have accounted for nearly 1/3 of the total purchase amount of chemical drugs in public hospitals
.
It is noteworthy that this time when injections accounted for more than half, the number of foreign-funded pharmaceutical companies to choose from has increased significantly, and most of them are injections
.
However, Pfizer, AZ, etc.
finally unexpectedly did not appear in the list of candidates
.
With reference to the selection of the first four batches of national procurement, this means that at the beginning of a new day, the pharmaceutical market with a purchase amount of 55 billion yuan will gradually be reshaped
.
Advantageous companies such as Qilu and Kelun led the win
Among the 205 companies that participated in the fifth batch of national procurement bids, many of them got on the train "before closing
.
"
.
"
On the eve of the bid opening, 20 products including Metoprolol Tartrate Tablets, Ceftriaxone Sodium for Injection, Cefazolin Sodium for Injection, Cefuroxime Sodium for Injection, Docetaxel Injection, Lansoprazole for Injection, etc.
passed the agreement Sexual evaluation, catching up with the new round of national procurement and rewriting the competition pattern of varieties
.
passed the agreement Sexual evaluation, catching up with the new round of national procurement and rewriting the competition pattern of varieties
.
A typical case is the oral dosage form of metoprolol
.
This variety was still a "1+3" competition pattern last week, but at the last moment of closing, many companies "running" into the track, abruptly broke the situation and turned it into a "1+9" complex Situation
.
As one of the varieties with the largest agreed procurement base in the first year, Yuanda Pharmaceutical, Changzhou Siyao, Yiling Pharmaceutical, etc.
compete with AZ on the same stage
.
Judging from the results of the proposed selection, Changzhou Four Pharmaceuticals, Shaanxi Buchang High-tech Pharmaceuticals, Zhuhai Tongyuan Pharmaceuticals, Shanghai Xudong Haipu Pharmaceuticals, Yiling Pharmaceuticals, Yuanda Pharmaceuticals and Yantai Juxian Pharmaceuticals were finally selected
.
For example, Xudong Haipu Pharmaceutical won the Beijing and other markets with 2.
34 yuan (50mg*20 tablets/box), and Yiling Pharmaceutical won the Tianjin and other markets with 1.
85 yuan (25mg*10 tablets/plate, 3 boards/box)
.
Among them, there are many companies that have just caught up with the "last train" to participate in the bidding and have eaten a large variety of over 1 billion
.
.
This variety was still a "1+3" competition pattern last week, but at the last moment of closing, many companies "running" into the track, abruptly broke the situation and turned it into a "1+9" complex Situation
.
As one of the varieties with the largest agreed procurement base in the first year, Yuanda Pharmaceutical, Changzhou Siyao, Yiling Pharmaceutical, etc.
compete with AZ on the same stage
.
Judging from the results of the proposed selection, Changzhou Four Pharmaceuticals, Shaanxi Buchang High-tech Pharmaceuticals, Zhuhai Tongyuan Pharmaceuticals, Shanghai Xudong Haipu Pharmaceuticals, Yiling Pharmaceuticals, Yuanda Pharmaceuticals and Yantai Juxian Pharmaceuticals were finally selected
.
For example, Xudong Haipu Pharmaceutical won the Beijing and other markets with 2.
34 yuan (50mg*20 tablets/box), and Yiling Pharmaceutical won the Tianjin and other markets with 1.
85 yuan (25mg*10 tablets/plate, 3 boards/box)
.
Among them, there are many companies that have just caught up with the "last train" to participate in the bidding and have eaten a large variety of over 1 billion
.
Intense not fierce! Accidents are not accidents! In fact, there are far more companies that are secretly competing.
The fifth batch of countries have adopted four major cephalosporin antibiotics: cefuroxime, ceftriaxone, ceftazidime, and cefazolin sodium
.
According to data from Minai.
com, the total terminal sales of these four cephalosporin antibiotics in public medical institutions will exceed 10 billion yuan in 2020
.
The fifth batch of countries have adopted four major cephalosporin antibiotics: cefuroxime, ceftriaxone, ceftazidime, and cefazolin sodium
.
According to data from Minai.
com, the total terminal sales of these four cephalosporin antibiotics in public medical institutions will exceed 10 billion yuan in 2020
.
The market competition is extremely fierce: Ceftriaxone sodium for injection has four pharmaceutical companies from Shanghai Shangyao Xinya Pharmaceutical, Shenzhen Lijian Pharmaceutical, Kunming Jida Pharmaceutical, and Sinopharm Zhijun (Shenzhen) Pharmaceutical Co.
, Ltd.
In the end, 10 companies including Sinopharm Zhongnuo were selected, including Lijian Pharmaceuticals in Zhejiang, Guangdong, and Tibet at 26.
6 yuan (1g*10 bottles/box), and 12.
38 yuan (0.
25g*10 bottles/box).
Box) Quotations were obtained from Sinopharm Zhijun Pharmaceuticals in 4 provinces including Shandong, Henan and Guizhou; while for injection of Cefazolin sodium, Hebei Huamin Pharmaceuticals of North China Pharmaceuticals and Sinopharm Group Zhongnuo Pharmaceuticals (Shijiazhuang) joined the battle
.
The original three-part structure of Huidisen Pharmaceutical, Runze Pharmaceutical and GSK was broken
.
, Ltd.
In the end, 10 companies including Sinopharm Zhongnuo were selected, including Lijian Pharmaceuticals in Zhejiang, Guangdong, and Tibet at 26.
6 yuan (1g*10 bottles/box), and 12.
38 yuan (0.
25g*10 bottles/box).
Box) Quotations were obtained from Sinopharm Zhijun Pharmaceuticals in 4 provinces including Shandong, Henan and Guizhou; while for injection of Cefazolin sodium, Hebei Huamin Pharmaceuticals of North China Pharmaceuticals and Sinopharm Group Zhongnuo Pharmaceuticals (Shijiazhuang) joined the battle
.
The original three-part structure of Huidisen Pharmaceutical, Runze Pharmaceutical and GSK was broken
.
In addition, azithromycin injections, levofloxacin injections, docetaxel injections, ropivacaine injections, gemcitabine injections and other products have similar competition patterns
.
It is not difficult to notice a phenomenon from the results of this proposed selection
.
The leading companies have more advantages .
For example, Colun, which is known for its injections, performed well.
Its levofloxacin sodium chloride injection, moxifloxacin hydrochloride eye drops, ceftazidime for injection and other related specifications were all shortlisted
.
.
It is not difficult to notice a phenomenon from the results of this proposed selection
.
The leading companies have more advantages .
For example, Colun, which is known for its injections, performed well.
Its levofloxacin sodium chloride injection, moxifloxacin hydrochloride eye drops, ceftazidime for injection and other related specifications were all shortlisted
.
The leading domestic companies such as Qilu, Yangtze River, China National Biotech, Hengrui, and Zhengda Tianqing are still the main players in the country
.
A total of 13 varieties of Qilu Pharmaceutical participated in the quotation, and 11 varieties were planned to be selected
.
Among them, the largest decrease was rivaroxaban (10mg), which dropped by 98%, and docetaxel dropped by 93.
71%
.
The same eye-catching clinical large-species budesonide inhalation (2ml: 1mg), Zhengda Tianqing, Healthy Yuantai Pharmaceutical and Sichuan Prime were selected at 5.
65 yuan/branch, 3.
39 yuan/branch and 2.
79 yuan/branch respectively.
The decline was 59.
75%, 75.
85% and 80.
12%, and the original research was finally eliminated
.
In 2019, among China's top 20 public medical institutions' terminal inhalation brands, budesonide ranked first, and domestic public hospitals' terminal sales have exceeded 7 billion yuan
.
In February 2020, CP Tianqing successfully won the first domestic imitation of budesonide suspension, breaking the situation that the original drug has been monopolizing the domestic market for 20 years
.
.
A total of 13 varieties of Qilu Pharmaceutical participated in the quotation, and 11 varieties were planned to be selected
.
Among them, the largest decrease was rivaroxaban (10mg), which dropped by 98%, and docetaxel dropped by 93.
71%
.
The same eye-catching clinical large-species budesonide inhalation (2ml: 1mg), Zhengda Tianqing, Healthy Yuantai Pharmaceutical and Sichuan Prime were selected at 5.
65 yuan/branch, 3.
39 yuan/branch and 2.
79 yuan/branch respectively.
The decline was 59.
75%, 75.
85% and 80.
12%, and the original research was finally eliminated
.
In 2019, among China's top 20 public medical institutions' terminal inhalation brands, budesonide ranked first, and domestic public hospitals' terminal sales have exceeded 7 billion yuan
.
In February 2020, CP Tianqing successfully won the first domestic imitation of budesonide suspension, breaking the situation that the original drug has been monopolizing the domestic market for 20 years
.
Overall, the level of competition broke a record
.
Rivaroxaban has the most declared companies, and the competition for cephalosporins is fierce, and foreign companies have quotations
.
The only exception is propranolol which is used to treat high blood pressure and other diseases
.
.
Rivaroxaban has the most declared companies, and the competition for cephalosporins is fierce, and foreign companies have quotations
.
The only exception is propranolol which is used to treat high blood pressure and other diseases
.
The variety of anti-tumor drugs has increased significantly
Judging from the list, another new feature is that the number of anti-tumor drugs participating in the national procurement has increased significantly compared with the previous four batches
.
.
Such as oxaliplatin
.
Hengrui has 8 varieties participating in the competition, including oxaliplatin injection, docetaxel injection, etc.
, and three large varieties with a market share of over 3 billion, oxaliplatin, docetaxel, and cisatrioxal benzenesulfonate.
Curonium injections are all selected
.
Sichuan Huiyu's docetaxel injections and oxaliplatin injections were also all selected
.
As far as oxaliplatin injection is concerned, Sanofi offered a price of 310.
51 yuan per box, a drop of more than 80%, and won 7 provinces and cities including Hebei and Jilin.
The remaining markets are divided by Hengrui, Qilu and Sichuan Huiyu.
Eat
.
.
Hengrui has 8 varieties participating in the competition, including oxaliplatin injection, docetaxel injection, etc.
, and three large varieties with a market share of over 3 billion, oxaliplatin, docetaxel, and cisatrioxal benzenesulfonate.
Curonium injections are all selected
.
Sichuan Huiyu's docetaxel injections and oxaliplatin injections were also all selected
.
As far as oxaliplatin injection is concerned, Sanofi offered a price of 310.
51 yuan per box, a drop of more than 80%, and won 7 provinces and cities including Hebei and Jilin.
The remaining markets are divided by Hengrui, Qilu and Sichuan Huiyu.
Eat
.
At present, the main products involved in the domestic market are oxaliplatin for injection, oxaliplatin mannitol injection, and oxaliplatin injection
.
According to data from Meinenet, the terminal sales of oxaliplatin injection in China's public medical institutions will exceed 3 billion yuan in 2020, and Sanofi will account for more than 60%
.
In June 2020, Qilu's oxaliplatin injection category 3 imitation listing application was approved and deemed to be reviewed, becoming its first company to review
.
In the bidding for oxaliplatin injection (50mg/bottle), Hengrui, Qilu, Sichuan Huiyu, and Sanofi bid for 91.
8 yuan/bottle, 198 yuan/bottle, 236.
8 yuan/bottle, and 310.
51 yuan respectively.
/ Branch won the bid, and bidding for anti-tumor drugs was more active
.
.
According to data from Meinenet, the terminal sales of oxaliplatin injection in China's public medical institutions will exceed 3 billion yuan in 2020, and Sanofi will account for more than 60%
.
In June 2020, Qilu's oxaliplatin injection category 3 imitation listing application was approved and deemed to be reviewed, becoming its first company to review
.
In the bidding for oxaliplatin injection (50mg/bottle), Hengrui, Qilu, Sichuan Huiyu, and Sanofi bid for 91.
8 yuan/bottle, 198 yuan/bottle, 236.
8 yuan/bottle, and 310.
51 yuan respectively.
/ Branch won the bid, and bidding for anti-tumor drugs was more active
.
Another example is docetaxel injection, a paclitaxel anti-tumor drug, which was finally shared by 6 companies including Hengrui, Zhengda Tianqing, Yangtze River, Qilu, Huiyu Pharmaceutical and Jiangsu Osaikang
.
As a therapeutic drug suitable for breast cancer and non-small cell lung cancer, the sales of terminal docetaxel injections in public medical institutions in China exceeded 4 billion yuan in 2019, a year-on-year decrease of 12.
71% in 2020
.
Analyzing its competitive landscape, there are more than 20 manufacturers of docetaxel injection, among which Hengrui has the largest market share, exceeding 40%, and Sanofi, the original research manufacturer, ranks second
.
The results of this round of national procurement did not see the original manufacturer of the drug
.
.
As a therapeutic drug suitable for breast cancer and non-small cell lung cancer, the sales of terminal docetaxel injections in public medical institutions in China exceeded 4 billion yuan in 2019, a year-on-year decrease of 12.
71% in 2020
.
Analyzing its competitive landscape, there are more than 20 manufacturers of docetaxel injection, among which Hengrui has the largest market share, exceeding 40%, and Sanofi, the original research manufacturer, ranks second
.
The results of this round of national procurement did not see the original manufacturer of the drug
.
The normalization of national procurement forces the transformation of pharmaceutical companies
In terms of pharmaceutical formulations, injections accounted for half, and the amount involved accounted for 70%, becoming the main formulation of this centralized procurement
.
Analyzing the market performance of the first four batches of nationally sourced varieties, it is not difficult to find that as the formulations of related varieties are included in centralized procurement, the corresponding market structure of similar varieties has also changed
.
For example, rosuvastatin calcium tablets and atorvastatin calcium tablets.
The comparison of the purchases of these two varieties and their similar varieties in sample hospitals in 2019 and 2018 shows that rosuvastatin calcium tablets and atorvastatin calcium tablets The purchase volume of the capsules and dispersible tablets has increased significantly, but the purchase volume of capsules and dispersible tablets has decreased
.
Obviously, in the market segment of oral statins, the competitive landscape of various preparations is adjusted rapidly after centralized procurement, especially among different preparations with the same generic name, the dosage forms that are included in the centralized procurement instead of the dosage forms that have not entered the centralized procurement
.
.
Analyzing the market performance of the first four batches of nationally sourced varieties, it is not difficult to find that as the formulations of related varieties are included in centralized procurement, the corresponding market structure of similar varieties has also changed
.
For example, rosuvastatin calcium tablets and atorvastatin calcium tablets.
The comparison of the purchases of these two varieties and their similar varieties in sample hospitals in 2019 and 2018 shows that rosuvastatin calcium tablets and atorvastatin calcium tablets The purchase volume of the capsules and dispersible tablets has increased significantly, but the purchase volume of capsules and dispersible tablets has decreased
.
Obviously, in the market segment of oral statins, the competitive landscape of various preparations is adjusted rapidly after centralized procurement, especially among different preparations with the same generic name, the dosage forms that are included in the centralized procurement instead of the dosage forms that have not entered the centralized procurement
.
This change in market trends has also brought about further accelerated transformation at the industrial level
.
.
On June 22, Xinlitai issued an announcement on the eve of National Procurement, stating that it would transfer all the company’s and its subsidiaries’ rights and interests of imatinib mesylate and its preparations in mainland China (except Hong Kong, Macao and Taiwan) to Medicines pharmaceutical Co.
, Ltd.
as one
.
Xinlitai explained that the transfer of the rights and interests related to the generic imatinib mesylate is aimed at further improving the efficiency of asset operations and focusing on the innovative research and development of key projects
.
After the transaction is completed, it is expected to generate investment income of approximately 4.
6 million yuan
.
, Ltd.
as one
.
Xinlitai explained that the transfer of the rights and interests related to the generic imatinib mesylate is aimed at further improving the efficiency of asset operations and focusing on the innovative research and development of key projects
.
After the transaction is completed, it is expected to generate investment income of approximately 4.
6 million yuan
.
Selling imatinib in this way, you can see its helplessness
.
At present, in addition to Xinlitai, CSPC Ouyi Pharmaceutical Co.
, Ltd.
, Hausen Pharmaceutical Co.
, Ltd.
, and Qilu Pharmaceutical Co.
, Ltd.
have also been reviewed
.
According to data from Minai.
com, the total sales of imatinib mesylate tablets in public hospitals across the country in 2020 will be 1.
62 billion yuan
.
.
At present, in addition to Xinlitai, CSPC Ouyi Pharmaceutical Co.
, Ltd.
, Hausen Pharmaceutical Co.
, Ltd.
, and Qilu Pharmaceutical Co.
, Ltd.
have also been reviewed
.
According to data from Minai.
com, the total sales of imatinib mesylate tablets in public hospitals across the country in 2020 will be 1.
62 billion yuan
.
To the surprise of the outside world, Xinlitai's imatinib only passed the consistency evaluation in May 2021, and now it has changed hands and decided to sell it
.
The big reason is that in 2019, the "4+7" expansion of the bid was opened, and the products of Hausen Pharmaceutical and Chia Tai Tianqing imatinib won the bid at 10.
38 yuan/tablet and 8.
93 yuan/tablet respectively
.
Missing the opportunity for centralized procurement, Xinlitai won the third over-evaluated variety of domestic imatinib mesylate tablets, and it seems that the win is not big
.
The blockbuster product affected by Guocai is also its first generic drug Taijia
.
Originally a year before Plavix entered the Chinese market, Xinlitai was the first to be approved for listing and quickly occupied the hospital market
.
However, in the second batch of national procurement in 2019, Sanofi successfully won the bid with a low price of 2.
54 yuan/piece, while Xinlitai’s price was 3.
13 yuan/piece, which was the highest price quoted by clopidogrel bidding companies at that time.
Litai was upset because of this
.
.
The big reason is that in 2019, the "4+7" expansion of the bid was opened, and the products of Hausen Pharmaceutical and Chia Tai Tianqing imatinib won the bid at 10.
38 yuan/tablet and 8.
93 yuan/tablet respectively
.
Missing the opportunity for centralized procurement, Xinlitai won the third over-evaluated variety of domestic imatinib mesylate tablets, and it seems that the win is not big
.
The blockbuster product affected by Guocai is also its first generic drug Taijia
.
Originally a year before Plavix entered the Chinese market, Xinlitai was the first to be approved for listing and quickly occupied the hospital market
.
However, in the second batch of national procurement in 2019, Sanofi successfully won the bid with a low price of 2.
54 yuan/piece, while Xinlitai’s price was 3.
13 yuan/piece, which was the highest price quoted by clopidogrel bidding companies at that time.
Litai was upset because of this
.
This time, Xinlitai has four more products planned to be selected from the fifth batch of national sources, including rivaroxaban tablets, benazepril, lercanidipine and cefuroxime sodium, which was only reviewed a few days ago
.
This represents the complex mentality of many traditional pharmaceutical companies in the transformation
.
.
This represents the complex mentality of many traditional pharmaceutical companies in the transformation
.
In short, it can be seen from the results of the proposed selection that, despite the fierce competition, there was no extremely high or extremely low quotation phenomenon in the national procurement this time, and the rational quotation was more prominent
.
355 products from 201 companies participated in the bidding, and 251 products from 148 companies were eligible for selection
.
Among them, 11 products from 10 foreign-funded enterprises are planned to be selected, 240 products from 138 domestic enterprises are to be selected, and the number of foreign-funded enterprises to be selected is the highest ever in centralized procurement
.
.
355 products from 201 companies participated in the bidding, and 251 products from 148 companies were eligible for selection
.
Among them, 11 products from 10 foreign-funded enterprises are planned to be selected, 240 products from 138 domestic enterprises are to be selected, and the number of foreign-funded enterprises to be selected is the highest ever in centralized procurement
.
It is reported that this centralized procurement adheres to the basic principle of "quantity and price linkage, recruitment and procurement integration", and further fine-tunes and perfects the rules on the basis of the "national organization, alliance procurement, platform operation" working mechanism: First, pay more attention to the supply of selected products Guarantee, further clarify the responsibility of enterprises to guarantee supply, and introduce clauses to determine candidate enterprises
.
The second is to include the prices of enterprises and the credit evaluation of recruitment and procurement into the selection clauses of centralized procurement, to support enterprises with good faith management and good performance records, and to restrict enterprises with untrustworthy violations and poor performance records
.
In terms of quality, we continue to adhere to the adoption of consistency evaluation as the threshold for generic drugs to participate in centralized procurement
.
.
The second is to include the prices of enterprises and the credit evaluation of recruitment and procurement into the selection clauses of centralized procurement, to support enterprises with good faith management and good performance records, and to restrict enterprises with untrustworthy violations and poor performance records
.
In terms of quality, we continue to adhere to the adoption of consistency evaluation as the threshold for generic drugs to participate in centralized procurement
.
The centralized procurement system has gradually improved and balanced its regulations in terms of quality, price, supply, and credit
.
Since its establishment, the National Medical Insurance Administration has carried out 5 batches of centralized drug purchases, covering 218 varieties, and involving a market capacity of 220 billion yuan
.
Recently, large-scale clinical real-world studies have also shown that the selected generic drugs have the same efficacy as the original drugs
.
In accordance with the requirements of normalized and institutionalized drug centralized procurement work, in the future, the scope of centralized drug procurement organized by the state will continue to expand, with clinical drug demand-oriented, ensuring drug quality and supply, and improving the benefit and sense of gain of the people
.
.
Since its establishment, the National Medical Insurance Administration has carried out 5 batches of centralized drug purchases, covering 218 varieties, and involving a market capacity of 220 billion yuan
.
Recently, large-scale clinical real-world studies have also shown that the selected generic drugs have the same efficacy as the original drugs
.
In accordance with the requirements of normalized and institutionalized drug centralized procurement work, in the future, the scope of centralized drug procurement organized by the state will continue to expand, with clinical drug demand-oriented, ensuring drug quality and supply, and improving the benefit and sense of gain of the people
.
Announcement Form of the Proposed Selection Results of National Drug Centralized Procurement
Medical Network News, June 24, after a whole day of intense and fierce confrontation, on the evening of June 23, Shanghai Sunshine Pharmaceutical Purchasing Network "overtime" announced overnight the results of the fifth batch of 62 nationally sourced varieties of the proposed selection.
3 days
.
Judging from the results of official announcements, a total of 61 products to be selected involve 148 companies, with an average price reduction of 56%
.
Among them, Qilu Pharmaceutical's rivaroxaban (10mg) successfully defeated the original research drug manufacturer Bayer with a 98% price reduction, becoming the highest drop in this round of nationally collected varieties
.
3 days
.
Judging from the results of official announcements, a total of 61 products to be selected involve 148 companies, with an average price reduction of 56%
.
Among them, Qilu Pharmaceutical's rivaroxaban (10mg) successfully defeated the original research drug manufacturer Bayer with a 98% price reduction, becoming the highest drop in this round of nationally collected varieties
.
At this point, the fifth batch of nationally sourced varieties that have attracted much attention from the industry has basically settled
.
According to reports, the nationally-sourced varieties have accounted for nearly 1/3 of the total purchase amount of chemical drugs in public hospitals
.
It is noteworthy that this time when injections accounted for more than half, the number of foreign-funded pharmaceutical companies to choose from has increased significantly, and most of them are injections
.
However, Pfizer, AZ, etc.
finally unexpectedly did not appear in the list of candidates
.
With reference to the selection of the first four batches of national procurement, this means that at the beginning of a new day, the pharmaceutical market with a purchase amount of 55 billion yuan will gradually be reshaped
.
.
According to reports, the nationally-sourced varieties have accounted for nearly 1/3 of the total purchase amount of chemical drugs in public hospitals
.
It is noteworthy that this time when injections accounted for more than half, the number of foreign-funded pharmaceutical companies to choose from has increased significantly, and most of them are injections
.
However, Pfizer, AZ, etc.
finally unexpectedly did not appear in the list of candidates
.
With reference to the selection of the first four batches of national procurement, this means that at the beginning of a new day, the pharmaceutical market with a purchase amount of 55 billion yuan will gradually be reshaped
.
Advantageous companies such as Qilu and Kelun led the win
Among the 205 companies that participated in the fifth batch of national procurement bids, many of them got on the train "before closing
.
"
.
"
On the eve of the bid opening, 20 products including Metoprolol Tartrate Tablets, Ceftriaxone Sodium for Injection, Cefazolin Sodium for Injection, Cefuroxime Sodium for Injection, Docetaxel Injection, Lansoprazole for Injection, etc.
passed the agreement Sexual evaluation, catching up with the new round of national procurement and rewriting the competition pattern of varieties
.
passed the agreement Sexual evaluation, catching up with the new round of national procurement and rewriting the competition pattern of varieties
.
A typical case is the oral dosage form of metoprolol
.
This variety was still a "1+3" competition pattern last week, but at the last moment of closing, many companies "running" into the track, abruptly broke the situation and turned it into a "1+9" complex Situation
.
As one of the varieties with the largest agreed procurement base in the first year, Yuanda Pharmaceutical, Changzhou Siyao, Yiling Pharmaceutical, etc.
compete with AZ on the same stage
.
Judging from the results of the proposed selection, Changzhou Four Pharmaceuticals, Shaanxi Buchang High-tech Pharmaceuticals, Zhuhai Tongyuan Pharmaceuticals, Shanghai Xudong Haipu Pharmaceuticals, Yiling Pharmaceuticals, Yuanda Pharmaceuticals and Yantai Juxian Pharmaceuticals were finally selected
.
For example, Xudong Haipu Pharmaceutical won the Beijing and other markets with 2.
34 yuan (50mg*20 tablets/box), and Yiling Pharmaceutical won the Tianjin and other markets with 1.
85 yuan (25mg*10 tablets/plate, 3 boards/box)
.
Among them, there are many companies that have just caught up with the "last train" to participate in the bidding and have eaten a large variety of over 1 billion
.
.
This variety was still a "1+3" competition pattern last week, but at the last moment of closing, many companies "running" into the track, abruptly broke the situation and turned it into a "1+9" complex Situation
.
As one of the varieties with the largest agreed procurement base in the first year, Yuanda Pharmaceutical, Changzhou Siyao, Yiling Pharmaceutical, etc.
compete with AZ on the same stage
.
Judging from the results of the proposed selection, Changzhou Four Pharmaceuticals, Shaanxi Buchang High-tech Pharmaceuticals, Zhuhai Tongyuan Pharmaceuticals, Shanghai Xudong Haipu Pharmaceuticals, Yiling Pharmaceuticals, Yuanda Pharmaceuticals and Yantai Juxian Pharmaceuticals were finally selected
.
For example, Xudong Haipu Pharmaceutical won the Beijing and other markets with 2.
34 yuan (50mg*20 tablets/box), and Yiling Pharmaceutical won the Tianjin and other markets with 1.
85 yuan (25mg*10 tablets/plate, 3 boards/box)
.
Among them, there are many companies that have just caught up with the "last train" to participate in the bidding and have eaten a large variety of over 1 billion
.
Intense not fierce! Accidents are not accidents! In fact, there are far more companies that are secretly competing.
The fifth batch of countries have adopted four major cephalosporin antibiotics: cefuroxime, ceftriaxone, ceftazidime, and cefazolin sodium
.
According to data from Minai.
com, the total terminal sales of these four cephalosporin antibiotics in public medical institutions will exceed 10 billion yuan in 2020
.
The fifth batch of countries have adopted four major cephalosporin antibiotics: cefuroxime, ceftriaxone, ceftazidime, and cefazolin sodium
.
According to data from Minai.
com, the total terminal sales of these four cephalosporin antibiotics in public medical institutions will exceed 10 billion yuan in 2020
.
The market competition is extremely fierce: Ceftriaxone sodium for injection has four pharmaceutical companies from Shanghai Shangyao Xinya Pharmaceutical, Shenzhen Lijian Pharmaceutical, Kunming Jida Pharmaceutical, and Sinopharm Zhijun (Shenzhen) Pharmaceutical Co.
, Ltd.
In the end, 10 companies including Sinopharm Zhongnuo were selected, including Lijian Pharmaceuticals in Zhejiang, Guangdong, and Tibet at 26.
6 yuan (1g*10 bottles/box), and 12.
38 yuan (0.
25g*10 bottles/box).
Box) Quotations were obtained from Sinopharm Zhijun Pharmaceuticals in 4 provinces including Shandong, Henan and Guizhou; while for injection of Cefazolin sodium, Hebei Huamin Pharmaceuticals of North China Pharmaceuticals and Sinopharm Group Zhongnuo Pharmaceuticals (Shijiazhuang) joined the battle
.
The original three-part structure of Huidisen Pharmaceutical, Runze Pharmaceutical and GSK was broken
.
, Ltd.
In the end, 10 companies including Sinopharm Zhongnuo were selected, including Lijian Pharmaceuticals in Zhejiang, Guangdong, and Tibet at 26.
6 yuan (1g*10 bottles/box), and 12.
38 yuan (0.
25g*10 bottles/box).
Box) Quotations were obtained from Sinopharm Zhijun Pharmaceuticals in 4 provinces including Shandong, Henan and Guizhou; while for injection of Cefazolin sodium, Hebei Huamin Pharmaceuticals of North China Pharmaceuticals and Sinopharm Group Zhongnuo Pharmaceuticals (Shijiazhuang) joined the battle
.
The original three-part structure of Huidisen Pharmaceutical, Runze Pharmaceutical and GSK was broken
.
In addition, azithromycin injections, levofloxacin injections, docetaxel injections, ropivacaine injections, gemcitabine injections and other products have similar competition patterns
.
It is not difficult to notice a phenomenon from the results of this proposed selection
.
The leading companies have more advantages .
For example, Colun, which is known for its injections, performed well.
Its levofloxacin sodium chloride injection, moxifloxacin hydrochloride eye drops, ceftazidime for injection and other related specifications were all shortlisted
.
.
It is not difficult to notice a phenomenon from the results of this proposed selection
.
The leading companies have more advantages .
For example, Colun, which is known for its injections, performed well.
Its levofloxacin sodium chloride injection, moxifloxacin hydrochloride eye drops, ceftazidime for injection and other related specifications were all shortlisted
.
The leading domestic companies such as Qilu, Yangtze River, China National Biotech, Hengrui, and Zhengda Tianqing are still the main players in the country
.
A total of 13 varieties of Qilu Pharmaceutical participated in the quotation, and 11 varieties were planned to be selected
.
Among them, the largest decrease was rivaroxaban (10mg), which dropped by 98%, and docetaxel dropped by 93.
71%
.
The same eye-catching clinical large-species budesonide inhalation (2ml: 1mg), Zhengda Tianqing, Healthy Yuantai Pharmaceutical and Sichuan Prime were selected at 5.
65 yuan/branch, 3.
39 yuan/branch and 2.
79 yuan/branch respectively.
The decline was 59.
75%, 75.
85% and 80.
12%, and the original research was finally eliminated
.
In 2019, among China's top 20 public medical institutions' terminal inhalation brands, budesonide ranked first, and domestic public hospitals' terminal sales have exceeded 7 billion yuan
.
In February 2020, CP Tianqing successfully won the first domestic imitation of budesonide suspension, breaking the situation that the original drug has been monopolizing the domestic market for 20 years
.
.
A total of 13 varieties of Qilu Pharmaceutical participated in the quotation, and 11 varieties were planned to be selected
.
Among them, the largest decrease was rivaroxaban (10mg), which dropped by 98%, and docetaxel dropped by 93.
71%
.
The same eye-catching clinical large-species budesonide inhalation (2ml: 1mg), Zhengda Tianqing, Healthy Yuantai Pharmaceutical and Sichuan Prime were selected at 5.
65 yuan/branch, 3.
39 yuan/branch and 2.
79 yuan/branch respectively.
The decline was 59.
75%, 75.
85% and 80.
12%, and the original research was finally eliminated
.
In 2019, among China's top 20 public medical institutions' terminal inhalation brands, budesonide ranked first, and domestic public hospitals' terminal sales have exceeded 7 billion yuan
.
In February 2020, CP Tianqing successfully won the first domestic imitation of budesonide suspension, breaking the situation that the original drug has been monopolizing the domestic market for 20 years
.
Overall, the level of competition broke a record
.
Rivaroxaban has the most declared companies, and the competition for cephalosporins is fierce, and foreign companies have quotations
.
The only exception is propranolol which is used to treat high blood pressure and other diseases
.
.
Rivaroxaban has the most declared companies, and the competition for cephalosporins is fierce, and foreign companies have quotations
.
The only exception is propranolol which is used to treat high blood pressure and other diseases
.
The variety of anti-tumor drugs has increased significantly
Judging from the list, another new feature is that the number of anti-tumor drugs participating in the national procurement has increased significantly compared with the previous four batches
.
.
Such as oxaliplatin
.
Hengrui has 8 varieties participating in the competition, including oxaliplatin injection, docetaxel injection, etc.
, and three large varieties with a market share of over 3 billion, oxaliplatin, docetaxel, and cisatrioxal benzenesulfonate.
Curonium injections are all selected
.
Sichuan Huiyu's docetaxel injections and oxaliplatin injections were also all selected
.
As far as oxaliplatin injection is concerned, Sanofi offered a price of 310.
51 yuan per box, a drop of more than 80%, and won 7 provinces and cities including Hebei and Jilin.
The remaining markets are divided by Hengrui, Qilu and Sichuan Huiyu.
Eat
.
.
Hengrui has 8 varieties participating in the competition, including oxaliplatin injection, docetaxel injection, etc.
, and three large varieties with a market share of over 3 billion, oxaliplatin, docetaxel, and cisatrioxal benzenesulfonate.
Curonium injections are all selected
.
Sichuan Huiyu's docetaxel injections and oxaliplatin injections were also all selected
.
As far as oxaliplatin injection is concerned, Sanofi offered a price of 310.
51 yuan per box, a drop of more than 80%, and won 7 provinces and cities including Hebei and Jilin.
The remaining markets are divided by Hengrui, Qilu and Sichuan Huiyu.
Eat
.
At present, the main products involved in the domestic market are oxaliplatin for injection, oxaliplatin mannitol injection, and oxaliplatin injection
.
According to data from Meinenet, the terminal sales of oxaliplatin injection in China's public medical institutions will exceed 3 billion yuan in 2020, and Sanofi will account for more than 60%
.
In June 2020, Qilu's oxaliplatin injection category 3 imitation listing application was approved and deemed to be reviewed, becoming its first company to review
.
In the bidding for oxaliplatin injection (50mg/bottle), Hengrui, Qilu, Sichuan Huiyu, and Sanofi bid for 91.
8 yuan/bottle, 198 yuan/bottle, 236.
8 yuan/bottle, and 310.
51 yuan respectively.
/ Branch won the bid, and bidding for anti-tumor drugs was more active
.
.
According to data from Meinenet, the terminal sales of oxaliplatin injection in China's public medical institutions will exceed 3 billion yuan in 2020, and Sanofi will account for more than 60%
.
In June 2020, Qilu's oxaliplatin injection category 3 imitation listing application was approved and deemed to be reviewed, becoming its first company to review
.
In the bidding for oxaliplatin injection (50mg/bottle), Hengrui, Qilu, Sichuan Huiyu, and Sanofi bid for 91.
8 yuan/bottle, 198 yuan/bottle, 236.
8 yuan/bottle, and 310.
51 yuan respectively.
/ Branch won the bid, and bidding for anti-tumor drugs was more active
.
Another example is docetaxel injection, a paclitaxel anti-tumor drug, which was finally shared by 6 companies including Hengrui, Zhengda Tianqing, Yangtze River, Qilu, Huiyu Pharmaceutical and Jiangsu Osaikang
.
As a therapeutic drug suitable for breast cancer and non-small cell lung cancer, the sales of terminal docetaxel injections in public medical institutions in China exceeded 4 billion yuan in 2019, a year-on-year decrease of 12.
71% in 2020
.
Analyzing its competitive landscape, there are more than 20 manufacturers of docetaxel injection, among which Hengrui has the largest market share, exceeding 40%, and Sanofi, the original research manufacturer, ranks second
.
The results of this round of national procurement did not see the original manufacturer of the drug
.
.
As a therapeutic drug suitable for breast cancer and non-small cell lung cancer, the sales of terminal docetaxel injections in public medical institutions in China exceeded 4 billion yuan in 2019, a year-on-year decrease of 12.
71% in 2020
.
Analyzing its competitive landscape, there are more than 20 manufacturers of docetaxel injection, among which Hengrui has the largest market share, exceeding 40%, and Sanofi, the original research manufacturer, ranks second
.
The results of this round of national procurement did not see the original manufacturer of the drug
.
The normalization of national procurement forces the transformation of pharmaceutical companies
In terms of pharmaceutical formulations, injections accounted for half, and the amount involved accounted for 70%, becoming the main formulation of this centralized procurement
.
Analyzing the market performance of the first four batches of nationally sourced varieties, it is not difficult to find that as the formulations of related varieties are included in centralized procurement, the corresponding market structure of similar varieties has also changed
.
For example, rosuvastatin calcium tablets and atorvastatin calcium tablets.
The comparison of the purchases of these two varieties and their similar varieties in sample hospitals in 2019 and 2018 shows that rosuvastatin calcium tablets and atorvastatin calcium tablets The purchase volume of the capsules and dispersible tablets has increased significantly, but the purchase volume of capsules and dispersible tablets has decreased
.
Obviously, in the market segment of oral statins, the competitive landscape of various preparations is adjusted rapidly after centralized procurement, especially among different preparations with the same generic name, the dosage forms that are included in the centralized procurement instead of the dosage forms that have not entered the centralized procurement
.
.
Analyzing the market performance of the first four batches of nationally sourced varieties, it is not difficult to find that as the formulations of related varieties are included in centralized procurement, the corresponding market structure of similar varieties has also changed
.
For example, rosuvastatin calcium tablets and atorvastatin calcium tablets.
The comparison of the purchases of these two varieties and their similar varieties in sample hospitals in 2019 and 2018 shows that rosuvastatin calcium tablets and atorvastatin calcium tablets The purchase volume of the capsules and dispersible tablets has increased significantly, but the purchase volume of capsules and dispersible tablets has decreased
.
Obviously, in the market segment of oral statins, the competitive landscape of various preparations is adjusted rapidly after centralized procurement, especially among different preparations with the same generic name, the dosage forms that are included in the centralized procurement instead of the dosage forms that have not entered the centralized procurement
.
This change in market trends has also brought about further accelerated transformation at the industrial level
.
.
On June 22, Xinlitai issued an announcement on the eve of National Procurement, stating that it would transfer all the company’s and its subsidiaries’ rights and interests of imatinib mesylate and its preparations in mainland China (except Hong Kong, Macao and Taiwan) to Medicines pharmaceutical Co.
, Ltd.
as one
.
Xinlitai explained that the transfer of the rights and interests related to the generic imatinib mesylate is aimed at further improving the efficiency of asset operations and focusing on the innovative research and development of key projects
.
After the transaction is completed, it is expected to generate investment income of approximately 4.
6 million yuan
.
, Ltd.
as one
.
Xinlitai explained that the transfer of the rights and interests related to the generic imatinib mesylate is aimed at further improving the efficiency of asset operations and focusing on the innovative research and development of key projects
.
After the transaction is completed, it is expected to generate investment income of approximately 4.
6 million yuan
.
Selling imatinib in this way, you can see its helplessness
.
At present, in addition to Xinlitai, CSPC Ouyi Pharmaceutical Co.
, Ltd.
, Hausen Pharmaceutical Co.
, Ltd.
, and Qilu Pharmaceutical Co.
, Ltd.
have also been reviewed
.
According to data from Minai.
com, the total sales of imatinib mesylate tablets in public hospitals across the country in 2020 will be 1.
62 billion yuan
.
.
At present, in addition to Xinlitai, CSPC Ouyi Pharmaceutical Co.
, Ltd.
, Hausen Pharmaceutical Co.
, Ltd.
, and Qilu Pharmaceutical Co.
, Ltd.
have also been reviewed
.
According to data from Minai.
com, the total sales of imatinib mesylate tablets in public hospitals across the country in 2020 will be 1.
62 billion yuan
.
To the surprise of the outside world, Xinlitai's imatinib only passed the consistency evaluation in May 2021, and now it has changed hands and decided to sell it
.
The big reason is that in 2019, the "4+7" expansion of the bid was opened, and the products of Hausen Pharmaceutical and Chia Tai Tianqing imatinib won the bid at 10.
38 yuan/tablet and 8.
93 yuan/tablet respectively
.
Missing the opportunity for centralized procurement, Xinlitai won the third over-evaluated variety of domestic imatinib mesylate tablets, and it seems that the win is not big
.
The blockbuster product affected by Guocai is also its first generic drug Taijia
.
Originally a year before Plavix entered the Chinese market, Xinlitai was the first to be approved for listing and quickly occupied the hospital market
.
However, in the second batch of national procurement in 2019, Sanofi successfully won the bid with a low price of 2.
54 yuan/piece, while Xinlitai’s price was 3.
13 yuan/piece, which was the highest price quoted by clopidogrel bidding companies at that time.
Litai was upset because of this
.
.
The big reason is that in 2019, the "4+7" expansion of the bid was opened, and the products of Hausen Pharmaceutical and Chia Tai Tianqing imatinib won the bid at 10.
38 yuan/tablet and 8.
93 yuan/tablet respectively
.
Missing the opportunity for centralized procurement, Xinlitai won the third over-evaluated variety of domestic imatinib mesylate tablets, and it seems that the win is not big
.
The blockbuster product affected by Guocai is also its first generic drug Taijia
.
Originally a year before Plavix entered the Chinese market, Xinlitai was the first to be approved for listing and quickly occupied the hospital market
.
However, in the second batch of national procurement in 2019, Sanofi successfully won the bid with a low price of 2.
54 yuan/piece, while Xinlitai’s price was 3.
13 yuan/piece, which was the highest price quoted by clopidogrel bidding companies at that time.
Litai was upset because of this
.
This time, Xinlitai has four more products planned to be selected from the fifth batch of national sources, including rivaroxaban tablets, benazepril, lercanidipine and cefuroxime sodium, which was only reviewed a few days ago
.
This represents the complex mentality of many traditional pharmaceutical companies in the transformation
.
.
This represents the complex mentality of many traditional pharmaceutical companies in the transformation
.
In short, it can be seen from the results of the proposed selection that, despite the fierce competition, there was no extremely high or extremely low quotation phenomenon in the national procurement this time, and the rational quotation was more prominent
.
355 products from 201 companies participated in the bidding, and 251 products from 148 companies were eligible for selection
.
Among them, 11 products from 10 foreign-funded enterprises are planned to be selected, 240 products from 138 domestic enterprises are to be selected, and the number of foreign-funded enterprises to be selected is the highest ever in centralized procurement
.
.
355 products from 201 companies participated in the bidding, and 251 products from 148 companies were eligible for selection
.
Among them, 11 products from 10 foreign-funded enterprises are planned to be selected, 240 products from 138 domestic enterprises are to be selected, and the number of foreign-funded enterprises to be selected is the highest ever in centralized procurement
.
It is reported that this centralized procurement adheres to the basic principle of "quantity and price linkage, recruitment and procurement integration", and further fine-tunes and perfects the rules on the basis of the "national organization, alliance procurement, platform operation" working mechanism: First, pay more attention to the supply of selected products Guarantee, further clarify the responsibility of enterprises to guarantee supply, and introduce clauses to determine candidate enterprises
.
The second is to include the prices of enterprises and the credit evaluation of recruitment and procurement into the selection clauses of centralized procurement, to support enterprises with good faith management and good performance records, and to restrict enterprises with untrustworthy violations and poor performance records
.
In terms of quality, we continue to adhere to the adoption of consistency evaluation as the threshold for generic drugs to participate in centralized procurement
.
.
The second is to include the prices of enterprises and the credit evaluation of recruitment and procurement into the selection clauses of centralized procurement, to support enterprises with good faith management and good performance records, and to restrict enterprises with untrustworthy violations and poor performance records
.
In terms of quality, we continue to adhere to the adoption of consistency evaluation as the threshold for generic drugs to participate in centralized procurement
.
The centralized procurement system has gradually improved and balanced its regulations in terms of quality, price, supply, and credit
.
Since its establishment, the National Medical Insurance Administration has carried out 5 batches of centralized drug purchases, covering 218 varieties, and involving a market capacity of 220 billion yuan
.
Recently, large-scale clinical real-world studies have also shown that the selected generic drugs have the same efficacy as the original drugs
.
In accordance with the requirements of normalized and institutionalized drug centralized procurement work, in the future, the scope of centralized drug procurement organized by the state will continue to expand, with clinical drug demand-oriented, ensuring drug quality and supply, and improving the benefit and sense of gain of the people
.
.
Since its establishment, the National Medical Insurance Administration has carried out 5 batches of centralized drug purchases, covering 218 varieties, and involving a market capacity of 220 billion yuan
.
Recently, large-scale clinical real-world studies have also shown that the selected generic drugs have the same efficacy as the original drugs
.
In accordance with the requirements of normalized and institutionalized drug centralized procurement work, in the future, the scope of centralized drug procurement organized by the state will continue to expand, with clinical drug demand-oriented, ensuring drug quality and supply, and improving the benefit and sense of gain of the people
.
Announcement Form of the Proposed Selection Results of National Drug Centralized Procurement
Medical Network News, June 24, after a whole day of intense and fierce confrontation, on the evening of June 23, Shanghai Sunshine Pharmaceutical Purchasing Network "overtime" announced overnight the results of the fifth batch of 62 nationally sourced varieties of the proposed selection.
3 days
.
Judging from the results of official announcements, a total of 61 products to be selected involve 148 companies, with an average price reduction of 56%
.
Among them, Qilu Pharmaceutical's rivaroxaban (10mg) successfully defeated the original research drug manufacturer Bayer with a 98% price reduction, becoming the highest drop in this round of nationally collected varieties
.
3 days
.
Judging from the results of official announcements, a total of 61 products to be selected involve 148 companies, with an average price reduction of 56%
.
Among them, Qilu Pharmaceutical's rivaroxaban (10mg) successfully defeated the original research drug manufacturer Bayer with a 98% price reduction, becoming the highest drop in this round of nationally collected varieties
.
At this point, the fifth batch of nationally sourced varieties that have attracted much attention from the industry has basically settled
.
According to reports, the nationally-sourced varieties have accounted for nearly 1/3 of the total purchase amount of chemical drugs in public hospitals
.
It is noteworthy that this time when injections accounted for more than half, the number of foreign-funded pharmaceutical companies to choose from has increased significantly, and most of them are injections
.
However, Pfizer, AZ, etc.
finally unexpectedly did not appear in the list of candidates
.
With reference to the selection of the first four batches of national procurement, this means that at the beginning of a new day, the pharmaceutical market with a purchase amount of 55 billion yuan will gradually be reshaped
.
.
According to reports, the nationally-sourced varieties have accounted for nearly 1/3 of the total purchase amount of chemical drugs in public hospitals
.
It is noteworthy that this time when injections accounted for more than half, the number of foreign-funded pharmaceutical companies to choose from has increased significantly, and most of them are injections
.
However, Pfizer, AZ, etc.
finally unexpectedly did not appear in the list of candidates
.
With reference to the selection of the first four batches of national procurement, this means that at the beginning of a new day, the pharmaceutical market with a purchase amount of 55 billion yuan will gradually be reshaped
.
Advantageous companies such as Qilu and Kelun led the win
Qilu, Cologne and other advantages of enterprise business enterprise led by winner Among the 205 companies that participated in the fifth batch of national procurement bids, many of them got on the train "before closing
.
"
.
"
On the eve of the bid opening, 20 products including Metoprolol Tartrate Tablets, Ceftriaxone Sodium for Injection, Cefazolin Sodium for Injection, Cefuroxime Sodium for Injection, Docetaxel Injection, Lansoprazole for Injection, etc.
passed the agreement Sexual evaluation, catching up with the new round of national procurement and rewriting the competition pattern of varieties
.
passed the agreement Sexual evaluation, catching up with the new round of national procurement and rewriting the competition pattern of varieties
.
A typical case is the oral dosage form of metoprolol
.
This variety was still a "1+3" competition pattern last week, but at the last moment of closing, many companies "running" into the track, abruptly broke the situation and turned it into a "1+9" complex Situation
.
As one of the varieties with the largest agreed procurement base in the first year, Yuanda Pharmaceutical, Changzhou Siyao, Yiling Pharmaceutical, etc.
compete with AZ on the same stage
.
Judging from the results of the proposed selection, Changzhou Four Pharmaceuticals, Shaanxi Buchang High-tech Pharmaceuticals, Zhuhai Tongyuan Pharmaceuticals, Shanghai Xudong Haipu Pharmaceuticals, Yiling Pharmaceuticals, Yuanda Pharmaceuticals and Yantai Juxian Pharmaceuticals were finally selected
.
For example, Xudong Haipu Pharmaceutical won the Beijing and other markets with 2.
34 yuan (50mg*20 tablets/box), and Yiling Pharmaceutical won the Tianjin and other markets with 1.
85 yuan (25mg*10 tablets/plate, 3 boards/box)
.
Among them, there are many companies that have just caught up with the "last train" to participate in the bidding and have eaten a large variety of over 1 billion
.
.
This variety was still a "1+3" competition pattern last week, but at the last moment of closing, many companies "running" into the track, abruptly broke the situation and turned it into a "1+9" complex Situation
.
As one of the varieties with the largest agreed procurement base in the first year, Yuanda Pharmaceutical, Changzhou Siyao, Yiling Pharmaceutical, etc.
compete with AZ on the same stage
.
Judging from the results of the proposed selection, Changzhou Four Pharmaceuticals, Shaanxi Buchang High-tech Pharmaceuticals, Zhuhai Tongyuan Pharmaceuticals, Shanghai Xudong Haipu Pharmaceuticals, Yiling Pharmaceuticals, Yuanda Pharmaceuticals and Yantai Juxian Pharmaceuticals were finally selected
.
For example, Xudong Haipu Pharmaceutical won the Beijing and other markets with 2.
34 yuan (50mg*20 tablets/box), and Yiling Pharmaceutical won the Tianjin and other markets with 1.
85 yuan (25mg*10 tablets/plate, 3 boards/box)
.
Among them, there are many companies that have just caught up with the "last train" to participate in the bidding and have eaten a large variety of over 1 billion
.
Intense not fierce! Accidents are not accidents! In fact, there are far more companies that are secretly competing.
The fifth batch of countries have adopted four major cephalosporin antibiotics: cefuroxime, ceftriaxone, ceftazidime, and cefazolin sodium
.
According to data from Minai.
com, the total terminal sales of these four cephalosporin antibiotics in public medical institutions will exceed 10 billion yuan in 2020
.
The fifth batch of countries have adopted four major cephalosporin antibiotics: cefuroxime, ceftriaxone, ceftazidime, and cefazolin sodium
.
According to data from Minai.
com, the total terminal sales of these four cephalosporin antibiotics in public medical institutions will exceed 10 billion yuan in 2020
.
The market competition is extremely fierce: Ceftriaxone sodium for injection has four pharmaceutical companies from Shanghai Shangyao Xinya Pharmaceutical, Shenzhen Lijian Pharmaceutical, Kunming Jida Pharmaceutical, and Sinopharm Zhijun (Shenzhen) Pharmaceutical Co.
, Ltd.
In the end, 10 companies including Sinopharm Zhongnuo were selected, including Lijian Pharmaceuticals in Zhejiang, Guangdong, and Tibet at 26.
6 yuan (1g*10 bottles/box), and 12.
38 yuan (0.
25g*10 bottles/box).
Box) Quotations were obtained from Sinopharm Zhijun Pharmaceuticals in 4 provinces including Shandong, Henan and Guizhou; while for injection of Cefazolin sodium, Hebei Huamin Pharmaceuticals of North China Pharmaceuticals and Sinopharm Group Zhongnuo Pharmaceuticals (Shijiazhuang) joined the battle
.
The original three-part structure of Huidisen Pharmaceutical, Runze Pharmaceutical and GSK was broken
.
, Ltd.
In the end, 10 companies including Sinopharm Zhongnuo were selected, including Lijian Pharmaceuticals in Zhejiang, Guangdong, and Tibet at 26.
6 yuan (1g*10 bottles/box), and 12.
38 yuan (0.
25g*10 bottles/box).
Box) Quotations were obtained from Sinopharm Zhijun Pharmaceuticals in 4 provinces including Shandong, Henan and Guizhou; while for injection of Cefazolin sodium, Hebei Huamin Pharmaceuticals of North China Pharmaceuticals and Sinopharm Group Zhongnuo Pharmaceuticals (Shijiazhuang) joined the battle
.
The original three-part structure of Huidisen Pharmaceutical, Runze Pharmaceutical and GSK was broken
.
In addition, azithromycin injections, levofloxacin injections, docetaxel injections, ropivacaine injections, gemcitabine injections and other products have similar competition patterns
.
It is not difficult to notice a phenomenon from the results of this proposed selection
.
The leading companies have more advantages .
For example, Colun, which is known for its injections, performed well.
Its levofloxacin sodium chloride injection, moxifloxacin hydrochloride eye drops, ceftazidime for injection and other related specifications were all shortlisted
.
.
It is not difficult to notice a phenomenon from the results of this proposed selection
.
The leading companies have more advantages .
For example, Colun, which is known for its injections, performed well.
Its levofloxacin sodium chloride injection, moxifloxacin hydrochloride eye drops, ceftazidime for injection and other related specifications were all shortlisted
.
The leading domestic companies such as Qilu, Yangtze River, China National Biotech, Hengrui, and Zhengda Tianqing are still the main players in the country
.
A total of 13 varieties of Qilu Pharmaceutical participated in the quotation, and 11 varieties were planned to be selected
.
Among them, the largest decrease was rivaroxaban (10mg), which dropped by 98%, and docetaxel dropped by 93.
71%
.
The same eye-catching clinical large-species budesonide inhalation (2ml: 1mg), Zhengda Tianqing, Healthy Yuantai Pharmaceutical and Sichuan Prime were selected at 5.
65 yuan/branch, 3.
39 yuan/branch and 2.
79 yuan/branch respectively.
The decline was 59.
75%, 75.
85% and 80.
12%, and the original research was finally eliminated
.
In 2019, among China's top 20 public medical institutions' terminal inhalation brands, budesonide ranked first, and domestic public hospitals' terminal sales have exceeded 7 billion yuan
.
In February 2020, CP Tianqing successfully won the first domestic imitation of budesonide suspension, breaking the situation that the original drug has been monopolizing the domestic market for 20 years
.
Health health health hospital hospital hospital.
A total of 13 varieties of Qilu Pharmaceutical participated in the quotation, and 11 varieties were planned to be selected
.
Among them, the largest decrease was rivaroxaban (10mg), which dropped by 98%, and docetaxel dropped by 93.
71%
.
The same eye-catching clinical large-species budesonide inhalation (2ml: 1mg), Zhengda Tianqing, Healthy Yuantai Pharmaceutical and Sichuan Prime were selected at 5.
65 yuan/branch, 3.
39 yuan/branch and 2.
79 yuan/branch respectively.
The decline was 59.
75%, 75.
85% and 80.
12%, and the original research was finally eliminated
.
In 2019, among China's top 20 public medical institutions' terminal inhalation brands, budesonide ranked first, and domestic public hospitals' terminal sales have exceeded 7 billion yuan
.
In February 2020, CP Tianqing successfully won the first domestic imitation of budesonide suspension, breaking the situation that the original drug has been monopolizing the domestic market for 20 years
.
Overall, the level of competition broke a record
.
Rivaroxaban has the most declared companies, and the competition for cephalosporins is fierce, and foreign companies have quotations
.
The only exception is propranolol which is used to treat high blood pressure and other diseases
.
.
Rivaroxaban has the most declared companies, and the competition for cephalosporins is fierce, and foreign companies have quotations
.
The only exception is propranolol which is used to treat high blood pressure and other diseases
.
The variety of anti-tumor drugs has increased significantly
The variety of anti-tumor drugs has increased significantly Judging from the list, another new feature is that the number of anti-tumor drugs participating in the national procurement has increased significantly compared with the previous four batches
.
.
Such as oxaliplatin
.
Hengrui has 8 varieties participating in the competition, including oxaliplatin injection, docetaxel injection, etc.
, and three large varieties with a market share of over 3 billion, oxaliplatin, docetaxel, and cisatrioxal benzenesulfonate.
Curonium injections are all selected
.
Sichuan Huiyu's docetaxel injections and oxaliplatin injections were also all selected
.
As far as oxaliplatin injection is concerned, Sanofi offered a price of 310.
51 yuan per box, a drop of more than 80%, and won 7 provinces and cities including Hebei and Jilin.
The remaining markets are divided by Hengrui, Qilu and Sichuan Huiyu.
Eat
.
.
Hengrui has 8 varieties participating in the competition, including oxaliplatin injection, docetaxel injection, etc.
, and three large varieties with a market share of over 3 billion, oxaliplatin, docetaxel, and cisatrioxal benzenesulfonate.
Curonium injections are all selected
.
Sichuan Huiyu's docetaxel injections and oxaliplatin injections were also all selected
.
As far as oxaliplatin injection is concerned, Sanofi offered a price of 310.
51 yuan per box, a drop of more than 80%, and won 7 provinces and cities including Hebei and Jilin.
The remaining markets are divided by Hengrui, Qilu and Sichuan Huiyu.
Eat
.
At present, the main products involved in the domestic market are oxaliplatin for injection, oxaliplatin mannitol injection, and oxaliplatin injection
.
According to data from Meinenet, the terminal sales of oxaliplatin injection in China's public medical institutions will exceed 3 billion yuan in 2020, and Sanofi will account for more than 60%
.
In June 2020, Qilu's oxaliplatin injection category 3 imitation listing application was approved and deemed to be reviewed, becoming its first company to review
.
In the bidding for oxaliplatin injection (50mg/bottle), Hengrui, Qilu, Sichuan Huiyu, and Sanofi bid for 91.
8 yuan/bottle, 198 yuan/bottle, 236.
8 yuan/bottle, and 310.
51 yuan respectively.
/ Branch won the bid, and bidding for anti-tumor drugs was more active
.
.
According to data from Meinenet, the terminal sales of oxaliplatin injection in China's public medical institutions will exceed 3 billion yuan in 2020, and Sanofi will account for more than 60%
.
In June 2020, Qilu's oxaliplatin injection category 3 imitation listing application was approved and deemed to be reviewed, becoming its first company to review
.
In the bidding for oxaliplatin injection (50mg/bottle), Hengrui, Qilu, Sichuan Huiyu, and Sanofi bid for 91.
8 yuan/bottle, 198 yuan/bottle, 236.
8 yuan/bottle, and 310.
51 yuan respectively.
/ Branch won the bid, and bidding for anti-tumor drugs was more active
.
Another example is docetaxel injection, a paclitaxel anti-tumor drug, which was finally shared by 6 companies including Hengrui, Zhengda Tianqing, Yangtze River, Qilu, Huiyu Pharmaceutical and Jiangsu Osaikang
.
As a therapeutic drug suitable for breast cancer and non-small cell lung cancer, the sales of terminal docetaxel injections in public medical institutions in China exceeded 4 billion yuan in 2019, a year-on-year decrease of 12.
71% in 2020
.
Analyzing its competitive landscape, there are more than 20 manufacturers of docetaxel injection, among which Hengrui has the largest market share, exceeding 40%, and Sanofi, the original research manufacturer, ranks second
.
The results of this round of national procurement did not see the original manufacturer of the drug
.
.
As a therapeutic drug suitable for breast cancer and non-small cell lung cancer, the sales of terminal docetaxel injections in public medical institutions in China exceeded 4 billion yuan in 2019, a year-on-year decrease of 12.
71% in 2020
.
Analyzing its competitive landscape, there are more than 20 manufacturers of docetaxel injection, among which Hengrui has the largest market share, exceeding 40%, and Sanofi, the original research manufacturer, ranks second
.
The results of this round of national procurement did not see the original manufacturer of the drug
.
The normalization of national procurement forces the transformation of pharmaceutical companies
The normalization of national procurement forces the transformation of pharmaceutical companies In terms of pharmaceutical formulations, injections accounted for half, and the amount involved accounted for 70%, becoming the main formulation of this centralized procurement
.
Analyzing the market performance of the first four batches of nationally sourced varieties, it is not difficult to find that as the formulations of related varieties are included in centralized procurement, the corresponding market structure of similar varieties has also changed
.
For example, rosuvastatin calcium tablets and atorvastatin calcium tablets.
The comparison of the purchases of these two varieties and their similar varieties in sample hospitals in 2019 and 2018 shows that rosuvastatin calcium tablets and atorvastatin calcium tablets The purchase volume of the capsules and dispersible tablets has increased significantly, but the purchase volume of capsules and dispersible tablets has decreased
.
Obviously, in the market segment of oral statins, the competitive landscape of various preparations is adjusted rapidly after centralized procurement, especially among different preparations with the same generic name, the dosage forms that are included in the centralized procurement instead of the dosage forms that have not entered the centralized procurement
.
.
Analyzing the market performance of the first four batches of nationally sourced varieties, it is not difficult to find that as the formulations of related varieties are included in centralized procurement, the corresponding market structure of similar varieties has also changed
.
For example, rosuvastatin calcium tablets and atorvastatin calcium tablets.
The comparison of the purchases of these two varieties and their similar varieties in sample hospitals in 2019 and 2018 shows that rosuvastatin calcium tablets and atorvastatin calcium tablets The purchase volume of the capsules and dispersible tablets has increased significantly, but the purchase volume of capsules and dispersible tablets has decreased
.
Obviously, in the market segment of oral statins, the competitive landscape of various preparations is adjusted rapidly after centralized procurement, especially among different preparations with the same generic name, the dosage forms that are included in the centralized procurement instead of the dosage forms that have not entered the centralized procurement
.
This change in market trends has also brought about further accelerated transformation at the industrial level
.
.
On June 22, Xinlitai issued an announcement on the eve of National Procurement, stating that it would transfer all the company’s and its subsidiaries’ rights and interests of imatinib mesylate and its preparations in mainland China (except Hong Kong, Macao and Taiwan) to Medicines pharmaceutical Co.
, Ltd.
as one
.
Xinlitai explained that the transfer of the rights and interests related to the generic imatinib mesylate is aimed at further improving the efficiency of asset operations and focusing on the innovative research and development of key projects
.
After the transaction is completed, it is expected to generate investment income of approximately 4.
6 million yuan
.
, Ltd.
as one
.
Xinlitai explained that the transfer of the rights and interests related to the generic imatinib mesylate is aimed at further improving the efficiency of asset operations and focusing on the innovative research and development of key projects
.
After the transaction is completed, it is expected to generate investment income of approximately 4.
6 million yuan
.
Selling imatinib in this way, you can see its helplessness
.
At present, in addition to Xinlitai, CSPC Ouyi Pharmaceutical Co.
, Ltd.
, Hausen Pharmaceutical Co.
, Ltd.
, and Qilu Pharmaceutical Co.
, Ltd.
have also been reviewed
.
According to data from Minai.
com, the total sales of imatinib mesylate tablets in public hospitals across the country in 2020 will be 1.
62 billion yuan
.
.
At present, in addition to Xinlitai, CSPC Ouyi Pharmaceutical Co.
, Ltd.
, Hausen Pharmaceutical Co.
, Ltd.
, and Qilu Pharmaceutical Co.
, Ltd.
have also been reviewed
.
According to data from Minai.
com, the total sales of imatinib mesylate tablets in public hospitals across the country in 2020 will be 1.
62 billion yuan
.
To the surprise of the outside world, Xinlitai's imatinib only passed the consistency evaluation in May 2021, and now it has changed hands and decided to sell it
.
The big reason is that in 2019, the "4+7" expansion of the bid was opened, and the products of Hausen Pharmaceutical and Chia Tai Tianqing imatinib won the bid at 10.
38 yuan/tablet and 8.
93 yuan/tablet respectively
.
Missing the opportunity for centralized procurement, Xinlitai won the third over-evaluated variety of domestic imatinib mesylate tablets, and it seems that the win is not big
.
The blockbuster product affected by Guocai is also its first generic drug Taijia
.
Originally a year before Plavix entered the Chinese market, Xinlitai was the first to be approved for listing and quickly occupied the hospital market
.
However, in the second batch of national procurement in 2019, Sanofi successfully won the bid with a low price of 2.
54 yuan/piece, while Xinlitai’s price was 3.
13 yuan/piece, which was the highest price quoted by clopidogrel bidding companies at that time.
Litai was upset because of this
.
.
The big reason is that in 2019, the "4+7" expansion of the bid was opened, and the products of Hausen Pharmaceutical and Chia Tai Tianqing imatinib won the bid at 10.
38 yuan/tablet and 8.
93 yuan/tablet respectively
.
Missing the opportunity for centralized procurement, Xinlitai won the third over-evaluated variety of domestic imatinib mesylate tablets, and it seems that the win is not big
.
The blockbuster product affected by Guocai is also its first generic drug Taijia
.
Originally a year before Plavix entered the Chinese market, Xinlitai was the first to be approved for listing and quickly occupied the hospital market
.
However, in the second batch of national procurement in 2019, Sanofi successfully won the bid with a low price of 2.
54 yuan/piece, while Xinlitai’s price was 3.
13 yuan/piece, which was the highest price quoted by clopidogrel bidding companies at that time.
Litai was upset because of this
.
This time, Xinlitai has four more products planned to be selected from the fifth batch of national sources, including rivaroxaban tablets, benazepril, lercanidipine and cefuroxime sodium, which was only reviewed a few days ago
.
This represents the complex mentality of many traditional pharmaceutical companies in the transformation
.
.
This represents the complex mentality of many traditional pharmaceutical companies in the transformation
.
In short, it can be seen from the results of the proposed selection that, despite the fierce competition, there was no extremely high or extremely low quotation phenomenon in the national procurement this time, and the rational quotation was more prominent
.
355 products from 201 companies participated in the bidding, and 251 products from 148 companies were eligible for selection
.
Among them, 11 products from 10 foreign-funded enterprises are planned to be selected, 240 products from 138 domestic enterprises are to be selected, and the number of foreign-funded enterprises to be selected is the highest ever in centralized procurement
.
.
355 products from 201 companies participated in the bidding, and 251 products from 148 companies were eligible for selection
.
Among them, 11 products from 10 foreign-funded enterprises are planned to be selected, 240 products from 138 domestic enterprises are to be selected, and the number of foreign-funded enterprises to be selected is the highest ever in centralized procurement
.
It is reported that this centralized procurement adheres to the basic principle of "quantity and price linkage, recruitment and procurement integration", and further fine-tunes and perfects the rules on the basis of the "national organization, alliance procurement, platform operation" working mechanism: First, pay more attention to the supply of selected products Guarantee, further clarify the responsibility of enterprises to guarantee supply, and introduce clauses to determine candidate enterprises
.
The second is to include the prices of enterprises and the credit evaluation of recruitment and procurement into the selection clauses of centralized procurement, to support enterprises with good faith management and good performance records, and to restrict enterprises with untrustworthy violations and poor performance records
.
In terms of quality, we continue to adhere to the adoption of consistency evaluation as the threshold for generic drugs to participate in centralized procurement
.
.
The second is to include the prices of enterprises and the credit evaluation of recruitment and procurement into the selection clauses of centralized procurement, to support enterprises with good faith management and good performance records, and to restrict enterprises with untrustworthy violations and poor performance records
.
In terms of quality, we continue to adhere to the adoption of consistency evaluation as the threshold for generic drugs to participate in centralized procurement
.
The centralized procurement system has gradually improved and balanced its regulations in terms of quality, price, supply, and credit
.
Since its establishment, the National Medical Insurance Administration has carried out 5 batches of centralized drug purchases, covering 218 varieties, and involving a market capacity of 220 billion yuan
.
Recently, large-scale clinical real-world studies have also shown that the selected generic drugs have the same efficacy as the original drugs
.
In accordance with the requirements of normalized and institutionalized drug centralized procurement work, in the future, the scope of centralized drug procurement organized by the state will continue to expand, with clinical drug demand-oriented, ensuring drug quality and supply, and improving the benefit and sense of gain of the people
.
Medicine, medicine, medicine.
Since its establishment, the National Medical Insurance Administration has carried out 5 batches of centralized drug purchases, covering 218 varieties, and involving a market capacity of 220 billion yuan
.
Recently, large-scale clinical real-world studies have also shown that the selected generic drugs have the same efficacy as the original drugs
.
In accordance with the requirements of normalized and institutionalized drug centralized procurement work, in the future, the scope of centralized drug procurement organized by the state will continue to expand, with clinical drug demand-oriented, ensuring drug quality and supply, and improving the benefit and sense of gain of the people
.
Announcement Form of the Proposed Selection Results of National Drug Centralized Procurement
